GSK names winners of 2015 Discovery Fast Track Challenge

GSKGSK has announced the winners of its third Discovery Fast Track Challenge. The programme is sponsored by GSK's Discovery Partnerships with Academia (DPAc) group to provide an opportunity for academic researchers in Europe and North America to collaborate with GSK and explore novel ideas for potential medicines. Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America. The selected proposals cover research related to discovery of potential new treatments for cancer, inflammatory bowel disease, HIV and kidney disease.

Investigators submitted proposals to screen their targets or biological pathways and, following a rigorous review process, finalists were invited to present their proposals to a panel of experienced drug discovery and therapeutic area experts from GSK. The winning proposals describe cutting-edge science that has the potential to impact disease areas where there is an unmet medical need and where patients would strongly benefit from new therapeutic interventions. The winners have access to GSK scientists and discovery resources, including high throughput screening with GSK’s compound libraries to further investigate the winning concepts.

The 2015 winning investigators are:

  • Dr. Miguel Fernandes & Professor Eduardo Salido, University of La Laguna, Spain
  • Professor Paul Lehner, University of Cambridge, UK
  • Professor Isabel Mérida, National Center for Biotechnology, Spanish National Research Council Madrid & Professors Mabel Loza and Ángel Carracedo of Innopharma, University of Santiago de Compostela, Spain
  • Dr. Efstratios Stratikos, National Center for Scientific Research "Demokritos", Greece
  • Dr. Nathalie Vergnolle, INSERM Toulouse, France
  • Dr. Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, USA

Duncan Holmes, European Head of DPAc, said: "The Discovery Fast Track Challenge has been extremely successful in identifying exciting new collaborative opportunities that may ultimately lead to innovative medicines to tackle unmet patient need. This program has extended our ability to reach out and make contacts with leading academics all across Europe and North America."

Carolyn Buser-Doepner, Worldwide Head of DPAc, said: "In this third round of the Discovery Fast Track Challenge, we have built on the momentum of this programme and have now seen a total of over 1000 proposals. From previous challenges, we have seen a number of exciting successes - both in terms of forging long-term partnerships towards finding medicines as well as identifying and transferring useful chemical tools to multiple winning researchers. We have similar expectations for this new wave of exciting opportunities!"

About Discovery Partnerships with Academia (DPAc)
Launched by GSK in late 2010, DPAc harnesses the deep biological and disease expertise of academia and the drug discovery know-how of GSK to form integrated teams that in partnership can discover new medicines for patients. GSK and the academic partner share the challenges and reward of innovation where GSK funds activities in the partner laboratories, as well as provides in-kind expertise and resources, to progress a programme from idea to medicine.

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]